4TZ4
 
 | | Crystal Structure of Human Cereblon in Complex with DDB1 and Lenalidomide | | 分子名称: | DNA damage-binding protein 1, Protein cereblon, S-Lenalidomide, ... | | 著者 | Chamberlain, P.P, Pagarigan, B, Delker, S, Leon, B, Riley, M. | | 登録日 | 2014-07-09 | | 公開日 | 2014-08-06 | | 最終更新日 | 2024-04-03 | | 実験手法 | X-RAY DIFFRACTION (3.01 Å) | | 主引用文献 | Structural Basis for Responsiveness to Thalidomide-Analog Drugs Defined by the Crystal Structure of the Human Cereblon:DDB1:Lenalidomide Complex
To Be Published
|
|
4TZU
 | | Crystal Structure of Murine Cereblon in Complex with Pomalidomide | | 分子名称: | Protein cereblon, S-Pomalidomide, SULFATE ION, ... | | 著者 | Chamberlain, P.P, Pagarigan, B, Delker, S, Leon, B. | | 登録日 | 2014-07-10 | | 公開日 | 2014-08-06 | | 最終更新日 | 2023-12-27 | | 実験手法 | X-RAY DIFFRACTION (2 Å) | | 主引用文献 | Structural Basis for Responsiveness to Thalidomide-Analog Drugs Defined by the Crystal Structure of the Human Cereblon:DDB1:Lenalidomide Complex
to be published
|
|
4TZC
 | | Crystal Structure of Murine Cereblon in Complex with Thalidomide | | 分子名称: | Protein cereblon, S-Thalidomide, SULFATE ION, ... | | 著者 | Chamberlain, P.P, Pagarigan, B, Delker, S, Leon, B. | | 登録日 | 2014-07-10 | | 公開日 | 2014-08-06 | | 最終更新日 | 2023-12-27 | | 実験手法 | X-RAY DIFFRACTION (1.88 Å) | | 主引用文献 | Structural Basis for Responsiveness to Thalidomide-Analog Drugs Defined by the Crystal Structure of the Human Cereblon:DDB1:Lenalidomide Complex
to be published
|
|
5HXB
 | | Cereblon in complex with DDB1, CC-885, and GSPT1 | | 分子名称: | 1-(3-chloro-4-methylphenyl)-3-({2-[(3S)-2,6-dioxopiperidin-3-yl]-1-oxo-2,3-dihydro-1H-isoindol-5-yl}methyl)urea, DNA damage-binding protein 1, Eukaryotic peptide chain release factor GTP-binding subunit ERF3A, ... | | 著者 | Chamberlain, P.P, Matyskiela, M, Pagarigan, B. | | 登録日 | 2016-01-30 | | 公開日 | 2016-06-29 | | 最終更新日 | 2023-09-27 | | 実験手法 | X-RAY DIFFRACTION (3.6 Å) | | 主引用文献 | A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase.
Nature, 535, 2016
|
|
5V3O
 | | Cereblon in complex with DDB1 and CC-220 | | 分子名称: | (3S)-3-[4-({4-[(morpholin-4-yl)methyl]phenyl}methoxy)-1-oxo-1,3-dihydro-2H-isoindol-2-yl]piperidine-2,6-dione, DNA damage-binding protein 1, Protein cereblon, ... | | 著者 | Matyskiela, M, Pagarigan, B, Chamberlain, P. | | 登録日 | 2017-03-07 | | 公開日 | 2017-05-03 | | 最終更新日 | 2018-02-07 | | 実験手法 | X-RAY DIFFRACTION (3.2 Å) | | 主引用文献 | A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos.
J. Med. Chem., 61, 2018
|
|
4OTI
 | | Crystal Structure of PRK1 Catalytic Domain in Complex with Tofacitinib | | 分子名称: | 3-{(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile, Serine/threonine-protein kinase N1 | | 著者 | Chamberlain, P.P, Delker, S, Pagarigan, B, Mahmoudi, A, Jackson, P, Abbassian, M, Muir, J, Raheja, N, Cathers, B. | | 登録日 | 2014-02-13 | | 公開日 | 2014-08-27 | | 最終更新日 | 2018-01-24 | | 実験手法 | X-RAY DIFFRACTION (1.93 Å) | | 主引用文献 | Crystal Structures of PRK1 in Complex with the Clinical Compounds Lestaurtinib and Tofacitinib Reveal Ligand Induced Conformational Changes.
Plos One, 9, 2014
|
|
4OTH
 | | Crystal Structure of PRK1 Catalytic Domain in Complex with Ro-31-8220 | | 分子名称: | BISINDOLYLMALEIMIDE IX, Serine/threonine-protein kinase N1 | | 著者 | Chamberlain, P.P, Delker, S, Pagarigan, B, Mahmoudi, A, Jackson, P, Abbassian, M, Muir, J, Raheja, N, Cathers, B. | | 登録日 | 2014-02-13 | | 公開日 | 2014-08-27 | | 最終更新日 | 2018-01-24 | | 実験手法 | X-RAY DIFFRACTION (1.8 Å) | | 主引用文献 | Crystal Structures of PRK1 in Complex with the Clinical Compounds Lestaurtinib and Tofacitinib Reveal Ligand Induced Conformational Changes.
Plos One, 9, 2014
|
|
4OTG
 | | Crystal Structure of PRK1 Catalytic Domain in Complex with Lestaurtinib | | 分子名称: | Lestaurtinib, Serine/threonine-protein kinase N1 | | 著者 | Chamberlain, P.P, Delker, S, Pagarigan, B, Mahmoudi, A, Jackson, P, Abbassian, M, Muir, J, Raheja, N, Cathers, B. | | 登録日 | 2014-02-13 | | 公開日 | 2014-08-27 | | 最終更新日 | 2022-12-07 | | 実験手法 | X-RAY DIFFRACTION (2.6 Å) | | 主引用文献 | Crystal Structures of PRK1 in Complex with the Clinical Compounds Lestaurtinib and Tofacitinib Reveal Ligand Induced Conformational Changes.
Plos One, 9, 2014
|
|
4OTD
 | | Crystal Structure of PRK1 Catalytic Domain | | 分子名称: | Serine/threonine-protein kinase N1 | | 著者 | Chamberlain, P.P, Delker, S, Pagarigan, B, Mahmoudi, A, Jackson, P, Abbassian, M, Muir, J, Raheja, N, Cathers, B. | | 登録日 | 2014-02-13 | | 公開日 | 2014-08-27 | | 最終更新日 | 2018-01-24 | | 実験手法 | X-RAY DIFFRACTION (2 Å) | | 主引用文献 | Crystal Structures of PRK1 in Complex with the Clinical Compounds Lestaurtinib and Tofacitinib Reveal Ligand Induced Conformational Changes.
Plos One, 9, 2014
|
|
4WNM
 | | SYK catalytic domain in complex with a potent triazolopyridine inhibitor | | 分子名称: | N~3~-(tetrahydro-2H-pyran-4-yl)-N~6~-[5-(tetrahydro-2H-pyran-4-ylmethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]-1H-indazole-3,6-diamine, SULFATE ION, Tyrosine-protein kinase SYK | | 著者 | Jackson, P.J. | | 登録日 | 2014-10-13 | | 公開日 | 2016-01-20 | | 最終更新日 | 2023-12-27 | | 実験手法 | X-RAY DIFFRACTION (2.5 Å) | | 主引用文献 | A Novel Triazolopyridine-Based Spleen Tyrosine Kinase Inhibitor That Arrests Joint Inflammation.
Plos One, 11, 2016
|
|
6UML
 | | Structural Basis for Thalidomide Teratogenicity Revealed by the Cereblon-DDB1-SALL4-Pomalidomide Complex | | 分子名称: | DNA damage-binding protein 1, Protein cereblon, S-Pomalidomide, ... | | 著者 | Clayton, T.L, Matyskiela, M.E, Pagarigan, B.E, Tran, E.T, Chamberlain, P.P. | | 登録日 | 2019-10-09 | | 公開日 | 2020-04-15 | | 最終更新日 | 2023-10-11 | | 実験手法 | X-RAY DIFFRACTION (3.58 Å) | | 主引用文献 | Crystal structure of the SALL4-pomalidomide-cereblon-DDB1 complex.
Nat.Struct.Mol.Biol., 27, 2020
|
|
3WX2
 | | Mouse Cereblon thalidomide binding domain, native | | 分子名称: | Protein cereblon, SULFATE ION, ZINC ION | | 著者 | Mori, T, Ito, T, Hirano, Y, Yamaguchi, Y, Handa, H, Hakoshima, T. | | 登録日 | 2014-07-10 | | 公開日 | 2014-08-06 | | 最終更新日 | 2023-11-08 | | 実験手法 | X-RAY DIFFRACTION (2 Å) | | 主引用文献 | Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs
Nat.Struct.Mol.Biol., 21, 2014
|
|
3WX1
 | | Mouse Cereblon thalidomide binding domain, selenomethionine derivative | | 分子名称: | Protein cereblon, SULFATE ION, ZINC ION | | 著者 | Mori, T, Ito, T, Hirano, Y, Yamaguchi, Y, Handa, H, Hakoshima, T. | | 登録日 | 2014-07-10 | | 公開日 | 2014-08-06 | | 最終更新日 | 2014-09-17 | | 実験手法 | X-RAY DIFFRACTION (1.93 Å) | | 主引用文献 | Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs
Nat.Struct.Mol.Biol., 21, 2014
|
|
6N6O
 | | Crystal structure of the human TTK in complex with an inhibitor | | 分子名称: | 1,2-ETHANEDIOL, 4-({5-chloro-4-[(cis-4-hydroxy-4-methylcyclohexyl)oxy]-7H-pyrrolo[2,3-d]pyrimidin-2-yl}amino)-N,N-dimethyl-3-{[(2R)-1,1,1-trifluoropropan-2-yl]oxy}benzamide, Dual specificity protein kinase TTK, ... | | 著者 | Fenalti, G. | | 登録日 | 2018-11-26 | | 公開日 | 2019-05-15 | | 最終更新日 | 2019-05-22 | | 実験手法 | X-RAY DIFFRACTION (2.6 Å) | | 主引用文献 | Design and Optimization Leading to an Orally Active TTK Protein Kinase Inhibitor with Robust Single Agent Efficacy.
J.Med.Chem., 62, 2019
|
|
6B4W
 | | TTK in Complex with Inhibitor | | 分子名称: | 4-{[4-(cyclopentyloxy)-5-(2-methyl-1,3-benzoxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino}-3-methoxy-N-methylbenzamide, CACODYLATE ION, Dual specificity protein kinase TTK | | 著者 | Delker, S, Chamberlain, P.P. | | 登録日 | 2017-09-27 | | 公開日 | 2017-10-25 | | 最終更新日 | 2024-03-13 | | 実験手法 | X-RAY DIFFRACTION (2.9 Å) | | 主引用文献 | The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen.
J. Med. Chem., 60, 2017
|
|
7MYZ
 | |
1O63
 | |
1O6C
 | |
1O66
 | |
1O60
 | |
1O67
 | |
1O62
 | |
1O64
 | |
1O65
 | |
1O61
 | |
